Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 17, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 17, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 213 Common Stock at $501.06 ($106,726) on August 17, 2026; holds 333,730 after (Indirect).
- Open-market sale: disposed of 427 Common Stock at $502.18 ($214,431) on August 17, 2026; holds 333,303 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $504.21 ($60,505) on August 17, 2026; holds 333,183 after (Indirect).
- Open-market sale: disposed of 1,238 Common Stock at $505.36 ($625,638) on August 17, 2026; holds 331,945 after (Indirect).
- Open-market sale: disposed of 2,521 Common Stock at $506.35 ($1,276,510) on August 17, 2026; holds 329,424 after (Indirect).
- Open-market sale: disposed of 3,298 Common Stock at $507.43 ($1,673,504) on August 17, 2026; holds 326,126 after (Indirect).
- Open-market sale: disposed of 1,683 Common Stock at $508.17 ($855,254) on August 17, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on August 17, 2026; holds 122,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,812,568 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-08-17 | Open-market sale | Common Stock | 213 | $501 | $106.7K | 333,730 |
| 2026-08-17 | Open-market sale | Common Stock | 427 | $502 | $214.4K | 333,303 |
| 2026-08-17 | Open-market sale | Common Stock | 120 | $504 | $60.5K | 333,183 |
| 2026-08-17 | Open-market sale | Common Stock | 1,238 | $505 | $625.6K | 331,945 |
| 2026-08-17 | Open-market sale | Common Stock | 2,521 | $506 | $1.3M | 329,424 |
| 2026-08-17 | Open-market sale | Common Stock | 3,298 | $507 | $1.7M | 326,126 |
| 2026-08-17 | Open-market sale | Common Stock | 1,683 | $508 | $855.3K | 324,443 |
| 2026-08-17 | Option exercise/conversion | Stock Option | 9,500 | — | — | 122,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Option exercise/conversion (9,500 shares) |
| 2026-08-17 | Open-market sale (213 shares) |
| 2026-08-17 | Open-market sale (427 shares) |
| 2026-08-17 | Open-market sale (120 shares) |
| 2026-08-17 | Open-market sale (1,238 shares) |
| 2026-08-17 | Open-market sale (2,521 shares) |
| 2026-08-17 | Open-market sale (3,298 shares) |
| 2026-08-17 | Open-market sale (1,683 shares) |
| 2026-08-17 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.